GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease

British Journal of Haematology

Volumn 175, Issue 1, 2016, Pages 141-153

  Oksenberg, Donna ^a   Dufu, Kobina ^a   Patel, Mira P ^a   Chuang, Chihyuan ^b   Li, Zhe ^a   Xu, Qing ^a   Silva Garcia, Abel ^a   Zhou, Chengjing ^c   Hutchaleelaha, Athiwat ^a   Patskovska, Larysa ^d,e   Patskovsky, Yury ^d,e   Almo, Steven C ^d   Sinha, Uma ^a   Metcalf, Brian W ^a   Archer, David R ^c  

^a Global Blood Therapeutics Inc ^*  (United States)

^b Cytokinetics Inc   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e Accent BioSystems   (United States)

Author keywords

haemoglobin; oxygen affinity; pharmacokinetics; sickle cell disease; sickle cell murine model; therapeutic

Indexed keywords

ANTIANEMIC AGENT; GTB 440; HEMOGLOBIN S; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ERYTHROCYTE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OXYGEN AFFINITY; OXYGEN DISSOCIATION CURVE; PLASMA HALF LIFE; POLYMERIZATION; PRIORITY JOURNAL; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; SICKLE CELL TRAIT;

EID: 85027922765     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14214     Document Type: Article

References (42)

1. Abdulmalik, O., Safo, M.K., Chen, Q., Yang, J., Brugnara, C., Ohene-Frempong, K., Abraham, D.J. & Asakura, T. (2005) 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. British Journal of Haematology, 128, 552–561.
2. Abdulmalik, O., Ghatge, M.S., Musayev, F.N., Parikh, A., Chen, Q., Yang, J., Nnamani, I., Danso-Danquah, R., Eseonu, D.N., Asakura, T., Abraham, D.J., Venitz, J. & Safo, M.K. (2011) Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Acta Crystallographica Section D, D67, 920–928.
3. Adachi, K. & Asakura, T. (1982) Kinetics of the polymerization of hemoglobin in high and low phosphate buffers. Blood Cells, 8, 213–224.
4. Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C.T., Sebastiani, P., Chui, D.H.K. & Steinberg, M.H. (2011) Fetal hemoglobin in sickle cell anemia. Blood, 118, 19–27.
5. Arya, R., Rolan, P.E., Wootton, R., Posner, J. & Bellingham, A.J. (1996) Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. British Journal of Haematology, 93, 817–821.
6. Ataga, K.I., Reid, M., Ballas, S.K., Yasin, Z., Bigelow, C., James, L.S., Smith, W.R., Galacteros, F., Kutlar, A., Hull, J.H. & Stocker, J.W. (2011) Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc. British Journal of Haematology, 153, 92–104.
7. Beddell, C.R., Goodford, P.J., Kneen, G., White, R.D., Wilkinson, S. & Wootton, R. (1984) Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. British Journal of Pharmacology, 82, 397–407.
8. Belcher, J., Nath, K. & Vercellotti, G. (2013) Vasculotoxic and proinflammatory effects of plasma heme: cell signaling and cytoprotective responses. ISRN Oxidative Medicine, 2013, 1–9.
9. Boyer, S.H., Belding, T.K., Margolet, L. & Noyes, a N. (1975) Fetal hemoglobin restriction to a few erythrocytes (F cells) in normal human adults. Science (New York, N.Y.), 188, 361–363.
10. Brandow, A. & Panepinto, J. (2013) Hydroxyurea use in sickle cell disease: the Battle with low rates of prescription, poor patient compliance and fears of toxicities and side effects. Expert Review Hematology, 3, 255–260.
11. Bunn, H.F. (1997) Pathogenesis and treatment of sickle cell disease. The New England Journal of Medicine, 337, 762–769.
12. Duarte, C.D., Greferath, R., Nicolau, C. & Lehn, J.-M. (2010) myo-Inositol trispyrophosphate: a novel allosteric effector of hemoglobin with high permeation selectivity across the red blood cell plasma membrane. Chembiochem : A European Journal of Chemical Biology, 11, 2543–2548.
13. Fitzharris, P., McLean, A.E., Sparks, R.G., Weatherley, B.C., White, R.D. & Wootton, R. (1985) The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve. British Journal of Clinical Pharmacology, 19, 471–481.
14. Goldberg, M.A., Husson, M.A. & Bunn, H.F. (1977) Participation of hemoglobins A and F in polymerization of sickle hemoglobin. The Journal of Biological Chemistry, 252, 3414–3421.
15. González Fernández, F.A., Villegas, A., Ropero, P., Carreño, M.D., Anguita, E., Polo, M., Pascual, A. & Henández, A. (2009) Haemoglobinopathies with high oxygen affinity. Experience of Erythropathology Cooperative Spanish Group. Annals of Hematology, 88, 235–238.
16. Guarnone, R., Centenara, E. & Barosi, G. (1995) Performance characteristics of Hemox-Analyzer for assessment of the hemoglobin dissociation curve. Haematologica, 80, 426–430.
17. He, Z. & Russell, J.E. (2002) A high-throughput microplate method for assessing aggregation of deoxygenated hemoglobin s heterotetramers in vitro. Analytical Biochemistry, 306, 349–352.
18. Imai, K., Tientadakul, P., Opartkiattikul, N., Luenee, P., Winichagoon, P., Svasti, J. & Fucharoen, S. (2001) Detection of haemoglobin variants and inference of their functional properties using complete oxygen dissociation curve measurements. British Journal of Haematology, 112, 483–487.
19. Kato, G.J., Lawrence, M.P., Mendelsohn, L.G., Saiyed, R., Wang, X., Ph, D., Conrey, A.K., Starling, J.M., Pharm, D., Grimes, G., Taylor, J.G., Mckew, J., Minniti, P. & Stern, W. (2013) Phase 1 clinical trial of the candidate anti-sickling agent Aes-103 in adults with sickle cell anemia. Blood, 122, 1009.
20. Kean, L.S., Brown, L.E., Nichols, J.W., Mohandas, N., Archer, D.R. & Hsu, L.L. (2002) Comparison of mechanisms of anemia in mice with sickle cell disease and β-thalassemia: peripheral destruction, ineffective erythropoiesis, and phospholipid scramblase-mediated phosphatidylserine exposure. Experimental Hematology, 30, 394–402.
21. Lehrer-Graiwer, J., Howard, J., Hemmaway, C.J., Awogbade, M., Telfer, P., Layton, M., Mant, T., Dufu, K., Hutchaleelaha, A., Koller, T., Oksenberg, D., Patel, M. & Ramos, E. (2015) GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease. Blood, 126, 542.
22. Manwani, D. & Frenette, P.S. (2013) Vaso-occlusion in sickle cell disease : pathophysiology and novel targeted therapies. Blood, 122, 3892–3898.
23. Marcus, S.J., Kinney, T.R., Schultz, W.H., O'Branski, E.E. & Ware, R.E. (1997) Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease. American Journal of Hematology, 54, 40–46.
24. McCurdy, P.R. & Sherman, A.S. (1978) Irreversibly sickled cells and red cell survival in sickle cell anemia. The American Journal of Medicine, 64, 253–258.
25. Mozzarelli, A., Hofrichter, J. & Eaton, W. (1987) Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science (New York, N.Y.), 237, 500–506.
26. Noguchi, C.T., Rodgers, G.P., Serjeant, G. & Schechter, A.N. (1988) Levels of fetal hemoglobin necessary for treatment of sickle cell disease. The New England Journal of Medicine, 318, 96–99.
27. Otwinowski, Z. & Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode. In: Macromolecular Crystallography, Part A, (ed. by J.N. Abelson, M.I. Simon, C.W. CarterJr & R.M. Sweet), pp. 307–326. Academic Press, New York.
28. 2 Affinity. Blood, 124, 1370.
29. Patskovska, L.N., Patskovsky, Y.V., Almo, S.C. & Hirsch, R.E. (2005) COHbC and COHbS crystallize in the R2 quaternary state at neutral pH in the presence of PEG 4000. Acta crystallographica. Section D, Biological Crystallography, 61, 566–573.
30. Rees, D.C., Williams, T.N. & Gladwin, M.T. (2010) Sickle-cell disease. Lancet, 376, 2018–2031.
31. Rolan, P.E., Parker, J.E., Gray, S.J., Weatherley, B.C., Ingram, J., Leavens, W., Wootton, R. & Posner, J. (1993) The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects. British Journal of Clinical Pharmacology, 35, 419–425.
32. Rolan, P.E., Mercer, A.J., Wootton, R. & Posner, J. (1995) Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers. British Journal of Clinical Pharmacology, 39, 375–380.
33. Safo, M.K. & Kato, G.J. (2014) Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematology/Oncology Clinics of North America, 28, 217–231.
34. Steinberg, M.H. (1999) Management of sickle cell disease. New England Journal of Medicine, 63, 1021–1030.
35. Steinberg, M.H. & Rodgers, G.P. (2001) Pharmacological Modulation of Fetal Hemoglobin. Medicine, 74, 301–304.
36. Steinberg, M.H., Lu, Z.H., Barton, F.B., Terrin, M.L., Charache, S. & Dover, G.J. (1997) Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood, 89, 1078–1088.
37. Sunshine, H.R., Hofrichter, J. & Eaton, W.A. (1978) Requirement for therapeutic inhibition of sickle haemoglobin gelation. Nature, 275, 238–240.
38. Telen, M.J., Wun, T., Mccavit, T.L., De Castro, L.M., Krishnamurti, L., Lanzkron, S., Hsu, L.L., Smith, W.R., Rhee, S., Magnani, J.L. & Thackray, H. (2015) Randomized phase 2 study of GMI-1070 in SCD : reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood, 125, 2656–2665.
39. Vagin, A.A., Steiner, R.A., Lebedev, A.A., Potterton, L., McNicholas, S., Long, F. & Murshudov, G.N. (2004) REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallographica Section D, Biological Crystallography, 60, 2184–2195.
40. Wahl, S. & Quirolo, K.C. (2009) Current issues in blood transfusion for sickle cell disease. Current Opinion in Pediatrics, 21, 15–21.
41. Wireko, F.C., Kellogg, G.E. & Abraham, D.J. (1991) Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors. Journal of Medicinal Chemistry, 34, 758–767.
42. Wu, L.-C., Sun, C.-W., Ryan, T.M., Pawlik, K.M., Ren, J. & Townes, T.M. (2006) Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood, 108, 1183–1188.